Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL
about
sameAs
A short Nur77-derived peptide converts Bcl-2 from a protector to a killerBcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapyBH3 mimetics to improve cancer therapy; mechanisms and examplesEvidence that membrane insertion of the cytosolic domain of Bcl-xL is governed by an electrostatic mechanismChemical genomics: what will it take and who gets to play?Targeting the apoptosis pathway in hematologic malignanciesPhotochemically enhanced binding of small molecules to the tumor necrosis factor receptor-1 inhibits the binding of TNF-Bcl-XL mutations suppress cellular sensitivity to antimycin AConformational Changes in Bcl-2 Pro-survival Proteins Determine Their Capacity to Bind LigandsERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cellsSelectivity by small-molecule inhibitors of protein interactions can be driven by protein surface fluctuationsAutophagy in cell death: an innocent convict?Small-molecule inhibitors of protein-protein interactions: progressing towards the dreamBacterial porin disrupts mitochondrial membrane potential and sensitizes host cells to apoptosis.Distinct functional and conformational states of the human lymphoid tyrosine phosphatase catalytic domain can be targeted by choice of the inhibitor chemotype.Recent advances in the development of anticancer agents targeting cell death inhibitors in the Bcl-2 protein family.What do we learn from high-throughput protein interaction data?Molecular recognition of protein surfaces: high affinity ligands for the CBP KIX domain.A competitive stapled peptide screen identifies a selective small molecule that overcomes MCL-1-dependent leukemia cell survivalAn integrative in silico approach for discovering candidates for drug-targetable protein-protein interactions in interactome dataThe mitochondrial effects of small organic ligands of BCL-2: sensitization of BCL-2-overexpressing cells to apoptosis by a pyrimidine-2,4,6-trione derivative.Modulation of Nr-13 antideath activity by peptide aptamers.Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity.Apogossypol derivatives as antagonists of antiapoptotic Bcl-2 family proteinsA general method for discovering inhibitors of protein-DNA interactions using photonic crystal biosensorsExpression of human Bcl-xL (Ser49) and (Ser62) mutants in Caenorhabditis elegans causes germline defects and aneuploidy.Inhibition of Bfl-1 with N-aryl maleimides.Oxidative stress by targeted agents promotes cytotoxicity in hematologic malignancies.High-throughput screening for modulators of protein-protein interactions: use of photonic crystal biosensors and complementary technologies.Virtual screening for potential inhibitors of Mcl-1 conformations sampled by normal modes, molecular dynamics, and nuclear magnetic resonance.A dual-readout F2 assay that combines fluorescence resonance energy transfer and fluorescence polarization for monitoring bimolecular interactions.Discovery and development of thiazolo[3,2-a]pyrimidinone derivatives as general inhibitors of Bcl-2 family proteins.Modulation of protein-protein interactions by synthetic receptors: design of molecules that disrupt serine protease-proteinaceous inhibitor interaction.Phosphoproteomic analysis of gossypol-induced apoptosis in ovarian cancer cell line, HOC1a.Selective small molecule inhibition of poly(ADP-ribose) glycohydrolase (PARG).Dysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunitiesRhodanine as a scaffold in drug discovery: a critical review of its biological activities and mechanisms of target modulation.Vinyl-triphenylamine dyes, a new family of switchable fluorescent probes for targeted two-photon cellular imaging: from DNA to protein labeling.Enhanced metabolic stability and protein-binding properties of artificial alpha helices derived from a hydrogen-bond surrogate: application to Bcl-xL.Molecular sequelae of proteasome inhibition in human multiple myeloma cells
P2860
Q24319007-AD9A7526-683F-4531-8E96-39941EF941E5Q24635408-04A90669-A5C1-4DDD-AF2B-2690F3162461Q24655483-70837B51-FF84-49F9-87C1-0E2500F23377Q24681039-D0019A09-3155-484C-BB20-56274F0E61AFQ24805615-ED328ADB-3F60-495A-A579-B10796CDB741Q27024422-1632A5C0-554C-43CC-8DFF-113895B641AEQ27635309-04695732-DA11-4D95-A8CD-6219DE5B893CQ27642316-D4831272-43AF-4F74-9D16-25F9A1CD66B0Q27657282-1E20817B-0D58-49BF-910C-7DA805CE4D49Q28307506-612B0C70-C71A-4A47-99B3-563B7A0268A7Q28543593-9755664E-53D2-46A4-973D-FF8DEC1CE0EAQ29617604-48219E45-77E8-4971-AE45-AEA969B1ABD0Q29617758-AC9B47D1-29DB-4059-8893-64C0E597F5A8Q30157077-9E0E53A7-3389-4DC1-BDC1-62DDDA64CECCQ30406901-9D5EED02-4B6F-410B-8936-719C864B65A8Q30971455-DAA58B86-391E-4FF9-81E2-6958442EAD5FQ30992459-A77B9A33-3DCE-4D24-BA74-F9D460715629Q31026926-A6E5568C-F964-463E-B075-5B04A8102465Q31100573-1CA3A3E2-4414-464E-82CC-17A46FAA8131Q31122058-4FC1D871-C571-499D-88A6-DB0DAF237AD3Q33234059-93D9E5D7-8BB1-4139-8B9B-1A150DA825A2Q33253911-911A6E97-0E41-4D51-A416-F4BB4AEB722DQ33392920-7A5C6683-9430-4351-853B-8A28D9868251Q33431139-4598D333-6815-4052-A7B7-AD4AA942C977Q33584683-DB10A99C-D78A-43A0-89E0-C53EC4D19593Q33648335-2AC1F51F-F761-4F9D-AA75-53EBB3F22FB5Q33713671-19708166-7897-4BB8-8948-1677D886B4EDQ33741142-F21565D3-7E2F-4B84-8DF7-0A669F8C6D53Q33765623-576515CD-13CD-4A59-AB87-D5AE3EB40B9BQ33834795-BD0705AE-2F1C-43DD-9527-395DFE42D4CBQ33843635-A9050F48-E27C-4695-B78E-4868EB5DB9AFQ33882002-3814410C-8731-4707-BCFB-C5BDC4FDE1BDQ34023516-CF195E36-25B1-467F-A1BC-962890EA9B13Q34087104-73642E08-3167-479A-968D-FA77C2905457Q34119303-A955F144-E6C1-4B85-810D-D08BCBAF6E97Q34139691-3A4A27CD-4F57-4094-8910-A6605F43D8F4Q34274409-887A2F1D-ACDC-4EE6-AA53-50B9D5BB5D4BQ34276503-DB82D8B2-E57B-4511-A978-64FEE7851698Q34313929-74EBD73B-491A-4C47-883A-334D1748D876Q34393832-C9401F03-B9BD-4601-A83B-190C56572852
P2860
Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Identification of small-molecu ...... ween the BH3 domain and Bcl-xL
@ast
Identification of small-molecu ...... ween the BH3 domain and Bcl-xL
@en
Identification of small-molecu ...... ween the BH3 domain and Bcl-xL
@nl
type
label
Identification of small-molecu ...... ween the BH3 domain and Bcl-xL
@ast
Identification of small-molecu ...... ween the BH3 domain and Bcl-xL
@en
Identification of small-molecu ...... ween the BH3 domain and Bcl-xL
@nl
prefLabel
Identification of small-molecu ...... ween the BH3 domain and Bcl-xL
@ast
Identification of small-molecu ...... ween the BH3 domain and Bcl-xL
@en
Identification of small-molecu ...... ween the BH3 domain and Bcl-xL
@nl
P2093
P3181
P356
P1433
P1476
Identification of small-molecu ...... ween the BH3 domain and Bcl-xL
@en
P2093
P2888
P304
P3181
P356
10.1038/35055085
P407
P577
2001-02-01T00:00:00Z
P5875
P6179
1031670473